Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR, ICPC Investigators
Am Heart J. 2018 198: 152-159

PMID: 29653637 · PMCID: PMC5903579 · DOI:10.1016/j.ahj.2017.12.010

MeSH Terms (17)

Acute Coronary Syndrome Aged Clopidogrel Female Genetic Association Studies Genome-Wide Association Study Humans Internationality Male Middle Aged Molecular Targeted Therapy Pharmacogenetics Prognosis Receptors, Purinergic P2Y12 Risk Assessment Survival Rate Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities:

Links